Network pharmacology results suggest that kaempferol-sensitizes pancreatic cancer cells to ERL treatment, and that this effcet may be associated with the PI3K/AKT signaling pathway and EGFR-TKI resistance. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.